VistaGen Therapeutics’ (VTGN) Outperform Rating Reiterated at William Blair

William Blair reissued their outperform rating on shares of VistaGen Therapeutics (NASDAQ:VTGN) in a research report released on Wednesday morning,RTT News reports. William Blair also issued estimates for VistaGen Therapeutics’ Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.48) EPS and Q4 2027 earnings at ($0.41) EPS.

VistaGen Therapeutics Stock Down 2.9%

VTGN opened at $2.00 on Wednesday. VistaGen Therapeutics has a 52 week low of $1.90 and a 52 week high of $4.21. The stock has a market cap of $58.32 million, a PE ratio of -1.20 and a beta of 0.70. The business has a 50 day moving average of $2.31 and a 200-day moving average of $2.57.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Tuesday, June 17th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.10. The business had revenue of ($0.01) million during the quarter, compared to analyst estimates of $0.18 million. VistaGen Therapeutics had a negative return on equity of 58.88% and a negative net margin of 6,777.08%. During the same quarter last year, the firm posted ($0.25) earnings per share. Equities analysts anticipate that VistaGen Therapeutics will post -1.77 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in VTGN. ADAR1 Capital Management LLC increased its holdings in shares of VistaGen Therapeutics by 246.4% during the first quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock valued at $1,052,000 after acquiring an additional 299,304 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in VistaGen Therapeutics during the 1st quarter valued at about $25,000. Two Sigma Advisers LP bought a new stake in VistaGen Therapeutics during the 4th quarter valued at about $35,000. Two Sigma Investments LP raised its holdings in VistaGen Therapeutics by 123.2% in the fourth quarter. Two Sigma Investments LP now owns 137,334 shares of the company’s stock worth $405,000 after buying an additional 75,792 shares during the last quarter. Finally, Stempoint Capital LP lifted its stake in shares of VistaGen Therapeutics by 26.1% in the fourth quarter. Stempoint Capital LP now owns 2,328,492 shares of the company’s stock worth $6,869,000 after buying an additional 481,700 shares in the last quarter. Hedge funds and other institutional investors own 78.39% of the company’s stock.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.